Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: Tipping the balance

被引:9
作者
Danese, Silvio
Pagano, Nico
Angelucci, Erika
Stefanelli, Tommaso
Repici, Alessandro
Omodei, Paolo
Daperno, Marco
Malesci, Alberto
机构
[1] Ist Clin Humanitas IRCCS Gastroenterol, Div Gastroenterol, Milan, Italy
[2] Univ Roma La Sapienza, Policlin Umberto 1, Div Gastroenterol, Rome, Italy
[3] ASO Ordine Mauriziano, Gastroenterol Unit, Turin, Italy
关键词
D O I
10.2174/092986707780831104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Crohn's disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti -inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) seems to play a central role in pathogenesis of CD. Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-alpha and its receptors. The aim of this paper is to critically review the rationale and state-of-the art for the use TNF-alpha inhibitors in the treatment of CD.
引用
收藏
页码:1489 / 1497
页数:9
相关论文
共 73 条
  • [61] CHIMERIC ANTI-TNF-ALPHA MONOCLONAL-ANTIBODY CA2 BINDS RECOMBINANT TRANSMEMBRANE TNF-ALPHA AND ACTIVATES IMMUNE EFFECTOR FUNCTIONS
    SCALLON, BJ
    MOORE, MA
    TRINH, H
    KNIGHT, DM
    GHRAYEB, J
    [J]. CYTOKINE, 1995, 7 (03) : 251 - 259
  • [62] A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
    Schreiber, S
    Rutgeerts, P
    Fedorak, RN
    Khaliq-Kareemi, M
    Kamm, MA
    Boivin, M
    Bernstein, CN
    Staun, M
    Thomsen, OO
    Innes, A
    [J]. GASTROENTEROLOGY, 2005, 129 (03) : 807 - 818
  • [63] Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept
    Shen, C
    Assche, GV
    Colpaert, S
    Maerten, P
    Geboes, K
    Rutgeerts, P
    Ceuppens, JL
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (03) : 251 - 258
  • [64] Risks and benefits of infliximab for the treatment of Crohn's disease
    Siegel, Corey A.
    Hur, Chin
    Korzenik, Joshua R.
    Gazelle, G. Scott
    Sands, Bruce E.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (08) : 1017 - 1024
  • [65] Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
    Stack, WA
    Mann, SD
    Roy, AJ
    Heath, P
    Sopwith, M
    Freeman, J
    Holmes, G
    Long, R
    Forbes, A
    Kamm, MA
    Hawkey, CJ
    [J]. LANCET, 1997, 349 (9051) : 521 - 524
  • [66] A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
    Targan, SR
    Hanauer, SB
    vanDeventer, SJH
    Mayer, L
    Present, DH
    Braakman, T
    DeWoody, KL
    Schaible, TF
    Rutgeerts, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (15) : 1029 - 1035
  • [67] Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
    ten Hove, T
    van Montfrans, C
    Peppelenbosch, MP
    van Deventer, SJH
    [J]. GUT, 2002, 50 (02) : 206 - 211
  • [68] Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
    Van Den Brande, JMH
    Braat, H
    Van Den Brink, GR
    Versteeg, HH
    Bauer, CA
    Hoedemaeker, I
    Van Montfrans, C
    Hommes, DW
    Peppelenbosch, MP
    Van Deventer, SJH
    [J]. GASTROENTEROLOGY, 2003, 124 (07) : 1774 - 1785
  • [69] Tumour necrosis factor and Crohn's disease
    VanDeventer, SJH
    [J]. GUT, 1997, 40 (04) : 443 - 448
  • [70] THE PATHOPHYSIOLOGY OF TUMOR NECROSIS FACTORS
    VASSALLI, P
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1992, 10 : 411 - 452